India 80 Percent Through Testing Drug Samples For Counterfeits
This article was originally published in PharmAsia News
India's Drug Controller General says the agency has collected 31,500 samples of drugs in its quest to determine which may be evading price regulations. The director of the agency said DCGI intends to enforce a new law that imposes stringent penalties on changes in drug compositions without its approval. Dr. Surinder Singh said some companies are evading price controls by retaining the brand name of the drugs after removing the active pharmaceutical ingredient subject to controls. State drug inspectors who collected the samples have examined about 80 percent of them in detail to determine which may be in violation. A report is expected to be issued in December. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.